GNFTF Stock News Genefit (GNFTF) 43.6500 07/25/2014 09:54:35

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genefit (GNFTF) 43.6500 $GNFTF

Global Abdominal Obesity Clinical Trials Review 2014
M2 - Mon May 19, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qkc4ph/abdominal_obesity) has announced the addition of the "Abdominal Obesity Global Clinical Trials Review, H1, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Abdominal Obesity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Abdominal Obesity. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Genfit SA - Lithera, Inc. - AstraZeneca PLC - Sanofi - Novartis AG - Hanmi Science Co., Ltd. - Parry Nutraceuticals - Kythera Biopharmaceuticals, Inc. - Johnson & Johnson - Queen's University - Massachusetts General Hospital - University of Pittsburgh - Wake Forest University - Baker IDI Heart and Diabetes Institute - Rush University Medical Center - UMC Utrecht Holding BV - Southeast University - Washington University School of Medicine - Maastricht University Medical Center For more information visit http://www.researchandmarkets.com/research/qk...al_obesity

Glucose Intolerance Clinical Trials Review 2014
M2 - Wed May 14, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nxjs95/glucose) has announced the addition of the "Glucose Intolerance Global Clinical Trials Review, H1, 2014" report to their offering. Glucose Intolerance Global Clinical Trials Review, H1, 2014" provides data on the Glucose Intolerance clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glucose Intolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glucose Intolerance. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Merck & Co., Inc. - Genfit SA - Novartis AG - N-Gene Research Laboratories, Inc. - Laboratoires Stella SA - Johnson & Johnson - Yale University - The National Institute of Diabetes and Digestive and Kidney Diseases - Hadassah Medical Organization - Maastricht University Medical Center - University of Oslo - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Universite de Sherbrooke - Academic Medical Center - University of Tasmania - Chinese University of Hong Kong For more information visit http://www.researchandmarkets.com/research/nxjs95/glucose

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - End of Forecast Surge in Sales for NASH from 2012-2017
M2 - Thu Mar 27, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/254n52/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update" report to their offering. The authors estimates the 2012 off-label sales for nonalcoholic steatohepatitis (NASH) to be approximately $233m across the US and five major European markets of France, Germany, Italy, Spain, and the UK. By forecast end in 2017, The authors expects sales to grow to about $1.36bn, with a compound annual growth rate (CAGR) of 42.2% across the 6MM. The authors expect the US to claim the most sales, contributing $1.28bn of global sales and a CAGR of 43.8%. Major drivers of growth in the NASH market are attributed to two factors: - The growing rate of obesity and diabetes globally. - The launch of Genfit's GFT505 and Intercept/DSP's obeticholic acid (OCA) in 2017. In OCA's favor, its Phase II/IIb trial was stopped early in January 2014, after a planned interim analysis showed that the primary endpoint of the study had been met. While for GFT505, Genfit is aligning itself to register GFT505 among the first approved therapies for NASH and the company received Fast Track designation for the GFT505 NASH program on February 14, 2014. - The authors expect the US' growth will be due in part to the launch of both of these products, while growth in the 5EU will be predominantly driven by GFT505 during the forecast period. Major barriers to the growth of the NASH market are attributed to: - Slow development of therapies specific for NASH. - Unclear understanding of the pathophysiology of NASH. - Inefficient diagnostic tools for NASH that may lead to delayed diagnosis of NASH. For more information visit http://www.researchandmarkets.com/research/25...ityanalyze About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven
M2 - Mon Mar 24, 4:30AM CDT
Summary

GENFIT: GFT505 Eliminates NASH and Fibrosis in a Clinically Relevant Disease Model
Business Wire - Wed Mar 19, 11:45AM CDT
GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new data from Professor Isabelle Leclercq of Universite Catholique de Louvain (Belgium) demonstrating the curative effects of GFT505 in an experimental model of NASH associated with metabolic disorders.

GENFIT TO HOLD A COMBINED GENERAL SHAREHOLDERS' MEETING ON APRIL 2, 2014
Thomson Reuters ONE - Wed Feb 26, 10:45AM CST
GENFIT TO HOLD A COMBINED GENERAL SHAREHOLDERS' MEETING ON APRIL 2, 2014

Cardiovascular Inflammation - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3br3p/cardiovascular) has announced the addition of the "Cardiovascular Inflammation - Pipeline Review, H2 2013" report to their offering. 'Cardiovascular Inflammation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Inflammation. Scope - A snapshot of the global therapeutic scenario for Cardiovascular Inflammation. - A review of the Cardiovascular Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cardiovascular Inflammation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cardiovascular Inflammation Overview Therapeutics Development Pipeline Products for Cardiovascular Inflammation - Overview Pipeline Products for Cardiovascular Inflammation - Comparative Analysis Cardiovascular Inflammation - Therapeutics under Development by Companies Cardiovascular Inflammation - Therapeutics under Investigation by Universities/Institutes Cardiovascular Inflammation - Pipeline Products Glance Clinical Stage Products Early Stage Products Cardiovascular Inflammation - Products under Development by Companies Cardiovascular Inflammation - Products under Investigation by Universities/Institutes Cardiovascular Inflammation - Companies Involved in Therapeutics Development Cardiovascular Inflammation - Therapeutics Assessment Drug Profiles trehalose - Drug Profile DMI-4983 - Drug Profile Drug For Inflammation In Ischemia Reperfusion Injury - Drug Profile SAVX-1 - Drug Profile FP-1115 - Drug Profile Cardiovascular Inflammation - Dormant Projects Cardiovascular Inflammation - Discontinued Products Appendix Companies Mentioned Genfit SA Priaxon AG Ampio Pharmaceuticals, Inc. NovelMed Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/n3...iovascular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets: 2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017
Business Wire - Wed Jan 22, 7:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/lmx4bb/opportunityanalyze) has announced the addition of the "2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017" report to their offering.

2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017
M2 - Wed Jan 22, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/b3szw2/opportunityanalyze) has announced the addition of the "2013 Report on the International Nonalcoholic Steatohepatitis (NASH) Market - Opportunity Analysis and Forecasts to 2017" report to their offering. The Nonalcoholic Steatohepatitis (NASH) market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit's PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma's FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class. Scope - Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management. - Analysis of the current and future market competition in the global NASH therapeutics market. - Pipeline analysis: comprehensive data split across Phase II/IIb, emerging trends and mechanisms of action under development, including: oral Proliferator Activated Receptor alpha, delta (PPARa,d) agonist, oral Farnesoid X Receptor (FXR) agonist, subcutaneous Lysyl Oxidase-Like 2 (LOXL2) inhibitor and subcutaneous Glucagon-like Peptide-1 (GLP-1) agonist. - Annualized NASH therapeutics market forecast, annual cost of therapy and treatment usage pattern data from 2012-2017. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. - Key topics covered include strategic clinical and commercial benchmarking assessment of the pipeline and standard of care, market outlook, R&D strategies, and unmet needs for the NASH therapeutics market. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Opportunity Analysis 7 R&D Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/b3...ityanalyze

Global Non-Alcoholic Steatohepatitis Clinical Trials Report - H2, 2013
M2 - Mon Jan 13, 10:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kv3lxq/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials - CATALYSIS, S.L. - Galmed International Ltd. - Genextra S.p.a. - Genfit SA - Gilead Sciences, Inc. - GlaxoSmithKline plc - Immuron Limited - LG Corp. - Phenex Pharmaceuticals AG - Raptor Pharmaceuticals Corp. Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - Yokohama City University - University of California, San Diego - Mayo Clinic - U.S. Department of Veterans Affairs - Hadassah Medical Organization - University of Michigan - The University of Texas Health Science Center at San Antonio - Imperial College London For more information visit http://www.researchandmarkets.com/research/kv...nalcoholic

GENFIT : HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES
Thomson Reuters ONE - Mon Jan 06, 10:45AM CST
HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES

Form 4: Update Filing for GP Strategies Corp (GPX)
Vickers Stock Research - Fri Jan 03, 6:08AM CST
GENFIT: IMPLEMENTATION OF THE FIRST INSTALLMENT (EUR1 M) OF A RESERVED CONVERTIBLE BOND LOAN AGREEMENT OF EUR8 M

Dyslipidemia - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pl2876/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2013" report to their offering. 'Dyslipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyslipidemia. Scope - A snapshot of the global therapeutic scenario for Dyslipidemia. - A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dyslipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Amgen Inc. Sanofi-Aventis Eli Lilly and Company Daiichi Sankyo Company, Ltd Merck & Co., Inc. Euroscreen S.A. Teijin Pharma Limited Novartis AG Biocon Limited Chong Kun Dang Pharmaceutical Dr. Reddy's Laboratories Limited Glenmark Pharmaceuticals Ltd. Kissei Pharmaceutical Co., Ltd. Kowa Company, Ltd. Zydus Cadila Healthcare Limited Bayer AG GW Pharmaceuticals plc Genfit Karo Bio Ligand Pharmaceuticals Incorporated and many more.... For more information visit http://www.researchandmarkets.com/research/pl...slipidemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Atherosclerosis - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n99vdc/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2013" report to their offering. 'Atherosclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Atherosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atherosclerosis. Scope - A snapshot of the global therapeutic scenario for Atherosclerosis. - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Atherosclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Merck & Co., Inc. Novartis AG Dong-A Pharmaceutical Co., Ltd. Dr. Reddy's Laboratories Limited Zydus Cadila Healthcare Limited Bayer AG Genfit PROLOR Biotech, Inc. CSL Limited Yuhan Corporation Anagen Therapeutics, Inc. Cytos Biotechnology AG Pronova BioPharma ASA AFFiRiS AG CIMAB S.A. and many more..... For more information visit http://www.researchandmarkets.com/research/n9...osclerosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2lr5mt/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2013" report to their offering. 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis. Scope - A snapshot of the global therapeutic scenario for Non-Alcoholic Steatohepatitis. - A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Isis Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Novo Nordisk A/S Mochida Pharmaceutical Co., Ltd. Norgine Limited Genfit Orchid Chemicals & Pharmaceuticals Ltd La Jolla Pharmaceutical Company Immuron Limited Raptor Pharmaceuticals Corp. Phenex Pharmaceuticals AG Wellstat Therapeutics Corporation Conatus Pharmaceuticals Inc. Intercept Pharmaceuticals, Inc. Obio Pharmaceutical Holdings Limited. NasVax Ltd. Stelic Institute & Co. Galmed International Ltd. Connexios Life Sciences Pvt. Ltd. For more information visit http://www.researchandmarkets.com/research/2l...nalcoholic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

GENFIT: TGFTX1 PROGRAM: GENFIT DISCLOSES ITS TECHNOLOGICAL ACCOMPLISHMENTS IN A NEW SCIENTIFIC PUBLICATION
Thomson Reuters ONE - Mon Aug 26, 1:30AM CDT
TGFTX1 PROGRAM: GENFIT DISCLOSES ITS TECHNOLOGICAL ACCOMPLISHMENTS IN A NEW SCIENTIFIC PUBLICATION

Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review - Latest Analysis
M2 - Wed Aug 21, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pv5b7/prediabetesimpai) has announced the addition of the "Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2013" report to their offering. Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2013" provides data on the Pre-Diabetes/Impaired Glucose Tolerance clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pre-Diabetes/Impaired Glucose Tolerance. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles - Arete Therapeutics Inc. - Bayer AG - Bioneer Corporation - Cadila Pharmaceuticals Ltd. - Daiichi Sankyo Company, Limited - Forest Laboratories, Inc. - Generex Biotechnology Corporation - Genfit SA - KineMed, Inc. - Limerick BioPharma, Inc. - Marico Limited - Merck & Co., Inc. - New Chapter, Inc. - Novartis AG - Novo Nordisk A/S - NuMe Health LLC - Resverlogix Corp. - Sanofi - Takeda Pharmaceutical Company Limited - UnitedHealth Group Incorporated For more information visit http://www.researchandmarkets.com/research/6p...betesimpai

GENFIT : GENFIT: CONVERSIONS INTO SHARES OF 30 BONDS OCA2012-2
Thomson Reuters ONE - Fri Aug 02, 10:45AM CDT
GENFIT: CONVERSIONS INTO SHARES OF 30 BONDS OCA2012-2

Liver Fibrosis - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fzcb9/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for liver fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for liver fibrosis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Liver Fibrosis. - A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Liver Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Liver Fibrosis Overview Therapeutics Development An Overview of Pipeline Products for Liver Fibrosis Companies Involved in Liver Fibrosis Therapeutics Development Liver Fibrosis - Therapeutics Assessment Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned - 7TM Pharma A/S - Angion Biomedica Corp - Bristol-Myers Squibb Company - Digna Biotech - FibroGen, Inc - GenKyoTex S.A - Genfit - Gilead Sciences, Inc - LG Life Sciences - La Jolla Pharmaceutical Company - Silence Therapeutics - Virobay Inc For more information visit http://www.researchandmarkets.com/research/8f...r_fibrosis

GENFIT: Description of the share buy-back program authorized by the combined shareholders' meeting of june 26, 2013
Thomson Reuters ONE - Fri Jul 26, 10:46AM CDT
GENFIT: DESCRIPTION OF THE SHARE BUY-BACK PROGRAM AUTHORIZED BY THE COMBINED SHAREHOLDERS' MEETING OF JUNE 26, 2013
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 51

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 84

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 39

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 76

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading

Top 5 Most Recently Viewed Articles

CEO of Cogent Communications to Showcase Company Updates

Updated Category News Views 112

Cogent Communications' CEO Will Share Insights at Key Conferences Cogent Communications Holdings, Inc. (NASDAQ: CCOI), recognized as one of the world's premier Internet service providers, has exciting news to share. Dave Schaeffer, the Chief Executive Officer, is set to present at two significant upcoming conferences, demonstrating leadership in the connectivity space....

Continue Reading
AnteraCapital 365 Unmasked: The Truth Behind Fraudulent Claims

Updated Category News Views 338

Understanding the Fraud of AnteraCapital 365 Be an informed investor – protect yourself against fraudulent schemes. The Canadian Investment Regulatory Organization (CIRO) has issued a warning regarding AnteraCapital 365. This fraudulent firm operates on multiple websites claiming to be associated with legitimate organizations, specifically, SIG North Trading, ULC. It is...

Continue Reading
Understanding the Liberty Broadband and Charter Merger Insights

Updated Category News Views 309

Rowley Law PLLC Conducts Investigation into Liberty Broadband Recently, Rowley Law PLLC has announced an investigation related to proposed acquisition activities involving Liberty Broadband Corporation (NASDAQ: LBRDA). This scrutiny comes amid news that Charter Communications, Inc. (NASDAQ: CHTR) intends to acquire Liberty Broadband. This proposed merger is set to impact...

Continue Reading
C3.ai Investors Urged to Act Now for Class Action Lawsuit

Updated Category News Views 198

C3.ai Investors Face Class Action Lawsuit The recent developments regarding C3.ai, Inc. (NYSE: AI) are significant for investors who have faced substantial losses. The former Attorney General of Louisiana, Charles C. Foti, Jr., alongside Kahn Swick & Foti, LLC, has reached out to stakeholders, reminding them of an impending deadline related to a class action lawsuit....

Continue Reading
JW Michaels Shares Insights on Salary Trends in Finance

Updated Category News Views 311

Understanding Executive Compensation in Financial Services Every year, companies and organizations strive to understand the nuances of compensation within the financial sector. JW Michaels & Co. recently released its latest Financial Services Market Data Report, offering valuable insights into executive remuneration practices for top-tier positions. This comprehensive...

Continue Reading